Поиск
  • Иванова Дарья

IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct two Phase


In early November, IPHARMA received two approvals from the Ministry of Health of the Russian Federation to conduct phase I clinical trials of Ventvil® and Slavinorm® medicinal products.

Protocol № HEP-VTL-01 "A double-blind, randomized, placebo-controlled study of the safety and tolerability of increasing doses of Ventvil® for single and subsequent multiple intramuscular administration in healthy volunteers."

The study objective is to evaluate the safety and tolerability of increasing doses of the drug with a single and subsequent multiple intramuscular administration in healthy volunteers.

Domain of usage: therapy, hepatic disorders.

Protocol No. CNS-SNM-01 "A double-blind, randomized, placebo-controlled study of the safety and tolerability of increasing doses of Slavinorm® for single and subsequent multiple intramuscular administration in healthy volunteers."

The study objective is to assessthe safety and tolerability of increasing doses of the drug with a single and subsequent multiple intramuscular administration in healthy volunteers.

Domain of usage: neurology (angioprotector).

Ventvil® and Slavinorm® are developed by the SIA Peptides company. It is a complex of polypeptides extracted from the organs and horns of cattle.

#PhaseI

Просмотров: 31

© 2020 IPHARMA

  • Facebook Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon